Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akebia Therapeutics, Inc. - Common Stock (NQ: AKBA )

1.690 -0.240 (-12.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Akebia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive
In the U.S., reimbursement of dialysis expenses by the Centers for Medicare & Medicaid Services (CMS) is done using a prospective payment system (PPS) which enables the payout of a predetermined amount... 
Via Benzinga
Looking Into Akebia Therapeutics's Return On Capital Employed
Via Benzinga
Akebia Therapeutics Earnings Preview
Akebia Therapeutics (NASDAQ:AKBA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Akebia... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  Thursday saw 177 companies set new 52-week lows. 
Via Benzinga
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick? 
Via TheNewswire.com
Akebia Therapeutics Return On Capital Employed Insights
  
Via Benzinga
Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study
Via Benzinga
Akebia Therapeutics: Q2 Earnings Insights
Akebia Therapeutics (NASDAQ:AKBA) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick?  
Via Benzinga
Why Missfresh Shares Are Trading Lower; Here Are 30 Stocks Moving Premarket
Gainers M-tron Industries, Inc. (NASDAQ: MPTI) rose 57.9% to $24.00 in pre-market trading after surging 10% on Friday. M-tron Industries completed its earlier announced separation from The LGL Group,... 
Via Benzinga
Why Kiora Pharmaceuticals Is Trading Lower By Around 22%; Here Are 26 Stocks Moving Premarket
Gainers 9 Meters Biopharma, Inc. (NASDAQ: NMTR) rose 31.4% to $0.2720 in pre-market trading after the company disclosed final results from Phase 2 VIBRANT study, End-of-Phase 2 meeting with the FDA for... 
Via Benzinga
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
By David Willey, Benzinga 
Via News Direct
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000... 
Via TheNewswire.com
Exposures Product Safety
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000... 
Via Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Amazon Is Trading Higher By 12%: Here Are 23 Stocks Moving Premarket
Gainers Getty Images Holdings, Inc. (NYSE: GETY) rose 104.5% to $21.47 in pre-market trading. 
Via Benzinga
Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday
Gainers Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64. Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to settle at $2.85 on Friday. 
Via Benzinga
REV Stock Moves Amid Revlon Bankruptcy, Short Squeeze Hopes
Revlon (REV) stock is on the move Friday as the volatility surrounding the meme stock continues following its bankruptcy announcement. 
Via InvestorPlace
U.S Stocks Turn Lower; Dow Tumbles Over 100 Points
U.S. stocks turned lower midway through trading, with the Dow Jones dropping more than 100 points on Friday. 
Via Benzinga
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday. 
Via Benzinga
Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today?
Akebia Therapeutics (AKBA) stock is taking off on Friday after the kidney treatment company revealed the return of rights for vadadustat. 
Via InvestorPlace
Why U.S. Stocks Are Trading Higher, Manufacturing Report And More
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. 
Via Benzinga
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, trader! It's time for another look at the biggest pre-market stock movers as we dive into the latest news for Friday! 
Via InvestorPlace
Akebia Therapeutics And 20 Stocks Moving Premarket
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 83.2% to $0.8250 in pre-market trading after dropping 10% on Thursday. 
Via Benzinga
Micron, Akebia Therapeutics And 3 Stocks To Watch Heading Into Friday
Some of the stocks that may grab investor focus today are: 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
Why Akebia Therapeutics Stock Is Soaring After Hours
Akebia Therapeutics Inc (NASDAQ: AKBA) shares are surging in Thursday's after-hours session after the company executed an agreement to terminate its Vadadustat collaboration and license agreements with... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.